Abstract:BACKGROUND: It is known that two-thirds of patients who develop clinical metastases following treatment of a primary cutaneous melanoma initially present with locoregional metastases and one-third initially present with distant metastases. However, few reports in the literature give detailed figures on different metastatic pathways in cutaneous melanoma.OBJECTIVES: The aim of the present study was to perform a detailed analysis of the different metastatic pathways, the time course of the development of metastases and the factors influencing them.METHODS: In a series of 3001 patients with primary cutaneous melanoma at first presentation, 466 subsequently developed metastasis and were followed-up over the long term at the University of Tuebingen, Germany between 1976 and 1996. Different pathways of metastatic spread were traced. Associated risk factors for the different pathways were assessed. Differences in survival probabilities were calculated by the Kaplan-Meier method and evaluated by the log-rank test.RESULTS: In 50.2% of the patients the first metastasis after treatment of the primary tumour developed in the regional lymph nodes. In the remaining half of the patient sample the first metastasis developed in the lymphatic drainage area in front of the regional lymph nodes, as satellite or in-transit metastases (21.7%) or as direct distant metastases (28.1%). Anatomical location, sex and tumour thickness were significant risk factors for the development of metastasis by different pathways. The most important risk factor appeared to be the location of the primary tumour. The median intervals elapsing before the first metastasis differed significantly between the different metastatic pathways. The direct distant metastases became manifest after a median period of 25 months, thus later than the direct regional lymph node metastases (median latency period, 16 months) and the direct satellite and in-transit metastases (median latency period, 17 months). In patients who developed distant metastases the period of development was independent of the metastatic route. The time at which the distant metastases developed was roughly the same (between 24 and 30 months after the detection of the primary tumour), irrespective of whether satellite or in-transit metastases, lymph node metastases or distant metastases were the first to occur.CONCLUSIONS: The time course of the development of distant metastasis was more or less the same irrespective of the metastatic pathway; this suggests that in patients with in-transit or satellite metastasis or regional lymph node metastasis, haematogenic metastatic spread had already taken place. Thus, the diagnostic value of sentinel lymph node biopsy and the therapeutic benefit of elective lymph node dissection may be limited, as satellite and in-transit metastases or direct distant metastases will not be detected and haematogenous spread may already have taken place when the intervention is performed.

Current concepts of metastasis in melanoma

Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy

Rethinking the biology of metastatic melanoma: a holistic approach

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

Metastasis: a question of life or death

Paradigm of biomarkers in metastatic melanoma (Review)

Metastatic uveal melanoma: The final frontier

Metastatic pathways in patients with cutaneous melanoma

Metabolic Mechanisms Regulating Distinct Steps of the Melanoma Metastatic Cascade

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Targeting metastatic melanoma

Identifying Metabolomic Features That Predict Metastasis of Melanoma from a Primary Site

Current Molecular Markers of Melanoma and Treatment Targets

Signal pathways of melanoma and targeted therapy

Cancer metastases: challenges and opportunities

Why is melanoma so metastatic?

Exploring Staging, Prognosis, and Treatment Innovations

Metastatic melanoma-A review of current and future perspective

Cellular Adhesion Pathways and Metastatic Potential of Human Melanoma

Targeting metastatic cancer

Metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization